Suwon-si, South Korea

Mi Kyeong Ju

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 11.0

ph-index = 4

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Mi Kyeong Ju: Innovator in Pharmaceutical Chemistry

Introduction

Mi Kyeong Ju is a prominent inventor based in Suwon-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of nine patents. His work focuses on developing innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Mi Kyeong Ju has developed triazolopyridin-3-ones or their salts, along with pharmaceutical compositions comprising these compounds. This technology provides processes for preparing triazolopyridin-3-ones, which exhibit inhibitory activity on VAP-1. These compounds can be effectively applied for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH). Additionally, he has patented triazolone derivatives or their salts, which also demonstrate selective inhibitory activity on VAP-1, further contributing to potential treatments for NASH.

Career Highlights

Mi Kyeong Ju is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has been instrumental in advancing research and development in the pharmaceutical sector.

Collaborations

He collaborates with notable colleagues, including Hyun Ho Choi and Tae Dong Han, to enhance the scope and impact of his research.

Conclusion

Mi Kyeong Ju's innovative work in pharmaceutical chemistry, particularly in developing compounds for treating NASH, showcases his significant contributions to the field. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…